logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Bilateral Tonicclonic Seizure With Generalized Onset

    FiltersReset Filters
    7 results

    • fycompa

      (perampanel)
      Eisai Inc.
      Usage: FYCOMPA is indicated for treating partial-onset seizures in patients aged 4 and older, and as adjunctive therapy for primary generalized tonic-clonic seizures in patients aged 12 and older.

    • lacosamide

      (lacosamide)
      Sintetica US LLC
      Usage: Lacosamide Injection is indicated for treating partial-onset seizures and as adjunctive therapy for primary generalized tonic-clonic seizures in patients aged 4 years and older.

    • levetiracetam

      (Levetiracetam)
      Tris Pharma Inc
      Usage: Levetiracetam is indicated for treating partial-onset seizures in patients aged 1 month and older. It is also approved as adjunctive therapy for myoclonic seizures in patients aged 12 and older with juvenile myoclonic epilepsy, and for primary generalized tonic-clonic seizures in patients aged 6 and older with idiopathic generalized epilepsy.

    • qudexy

      (Topiramate)
      Upsher-Smith Laboratories, LLC
      Usage: QUDEXY XR is indicated for the treatment of partial-onset and primary generalized tonic-clonic seizures as initial monotherapy or adjunctive therapy in patients aged 2 and older. It is also approved for the preventive treatment of migraines in patients aged 12 and older.

    • topiramate

      (topiramate spinkle)
      Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
      Usage: Topiramate is indicated for monotherapy in treating partial-onset or primary generalized tonic-clonic seizures in patients aged 2 and older. It is also used as adjunctive therapy for various types of seizures, including those associated with Lennox-Gastaut syndrome, and for the preventive treatment of migraine in patients aged 12 and older.

    • trokendi xr

      (topiramate)
      Supernus Pharmaceuticals
      Usage: TROKENDI XR® is indicated for initial monotherapy and adjunctive therapy in treating partial-onset and primary generalized tonic-clonic seizures, as well as seizures associated with Lennox-Gastaut syndrome in patients aged 6 and older. It is also indicated for preventive migraine treatment in patients aged 12 and older.

    • vimpat

      (lacosamide)
      UCB, Inc.
      Usage: VIMPAT is indicated for the treatment of partial-onset seizures in patients aged 1 month and older, and as adjunctive therapy for primary generalized tonic-clonic seizures in patients aged 4 years and older.